Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: T2 Biosystems; Everist Genomics, Tecan Group, DNAVision, PerkinElmer, Meyer Children's Hospital of Florence

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – T2 Biosystems has moved into a newly renovated 20,000-square-foot facility, more than doubling its size in Cambridge, Mass. The new space includes state-of-the-art laboratories to support the company's assay and instrument development as well as to support its diagnostic tests and systems.

Genetics Squared has changed its name to Everist Genomics and said it is ready to launch its first prognostic gene-based laboratory test, OncoDefender, to help in treatment decisions following surgery for Stage I and II colon cancer and Stage I rectal cancer.

The Tecan Group has signed an exclusive distribution agreement covering Attana's biosensor instruments and assay technology in North America. The agreement pertains to the Attana 100, 200, and Cell 200 platforms along with biosensors and accompanying assay reagents, as well as service and support.

Tecan also announced an original equipment manufacturing agreement with DiaSorin for the supply of a fully automated clinical ELISA platform and certain detection instruments. They will be used along with DiaSorin's Murex product line to diagnose HIV, HCV, and HBV infections. The agreement covers all countries outside the US.

European genetic analysis service firm DNAVision acquired four Life Technologies' next-generation sequencing platforms, including two 5500xl SOLiD systems. The 5500xl platforms will be used initially for whole human genome sequencing projects for its pharmaceutical and medical research customers, the company said.

PerkinElmer and the Meyer Children's Hospital of Florence, Italy, announced they have developed the NeoBase test for early-stage diagnosis of tyrosinemia type I. The test can be used to screen newborns for the disease within the first 48 hours of life, "enabling rapid diagnosis, and immediate intervention by clinicians, through diet modification, medication, or surgery," the two partners said.